Antihypertensive background therapy at baseline, n (%)	15 (75)	3 (60)
RAS inhibitors, n (%)	13 (87)	2 (67)
ACEIs, n	4	0
ARBs, n	9	2
ACEI+ARB, n	1	0
Spironolactone, n	2	0
Ca antagonists, n (%)	11 (73)	3 (60)
Diuretics, n (%)	0 (0)	1 (20)
β blockers, n (%)	1 (7)	1 (20)
α-Methyldopa, n (%)	2 (13)	0